Cookies notice

This website uses cookies. By continuing to use this website, you consent to our use of these cookies.

You can find out more about how we use cookies and how to manage them by reading our Cookie Policy.

Continue
Close
EN
 
EN

Mylan Worldwide

Close

Please select one of our websites from the list below.

  1. Africa

    1. South Africa
      1. English

  2. Americas

    1. Brazil
      1. Português brasileiro
    2. Canada
      1. English
      2. Français
    3. United States
      1. English

  3. Asia

    1. India
      1. English
    2. Japan
      1. 日本語

  4. Europe

    1. Austria
      1. Deutsch
    2. Belgium
      1. Français
      2. Nederlands
    3. Czech Republic
      1. Čeština
    4. Denmark
      1. Dansk
    5. Finland
      1. Suomi
    6. France
      1. Français
    7. Germany
      1. Deutsch
    8. Greece
      1. Ελληνικά
    9. Hungary
      1. Magyar
    10. Ireland
      1. English
    11. Italy
      1. Italiano
    12. Netherlands
      1. Nederlands
    13. Norway
      1. Norsk
    14. Poland
      1. Polski
    15. Portugal
      1. Português
    16. Slovakia
      1. Slovenský
    17. Slovenia
      1. Slovenian
    18. Spain
      1. Español
    19. Sweden
      1. Svensk
    20. Switzerland
      1. Deutsch
      2. English
    21. United Kingdom
      1. English

  5. Pacific

    1. Australia
      1. English
    2. New Zealand
      1. English

Mylan also is proud to do business in these locations.

  1. Morocco
  2. Taiwan
  1. Singapore
Search
Menu

  1. Learn About Mylan's Commitment to Social Responsibility

    Learn more>

  2. US FDA Approves Wixela

    U.S. FDA Approves Wixela(TM) Inhub(TM) (fluticasone propionate and salmeterol inhalation powder, USP)

  3. Growing with Purpose

    Meda acquisition bolsters portfolio, expands capabilities in OTC, women’s health, respiratory, allergy, dermatology and pain-management

  4. Always Moving Forward

    Innovation is a part of who we are and the reason we see opportunity in every challenge.

  5. Investor Day Highlights Durability of Mylan's Global Platform

    Mylan’s senior leadership showcased how Mylan is Built to Last through a deep dive into its one-of-a-kind commercial and operational platforms.

  6. Mylan Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Adalimumab Biosimilar in Europe

    Expanding access to biologics through the introduction of biosimilars around the world is a key area of focus for Mylan.

  1. Continuing Our Commitment to Fight HIV

    Mylan's HIV self-test kit allows you to take a proactive approach to your health and can help in the fight against the spread of HIV

    Mylan's HIV self-test kit allows you to take a proactive approach to your health and can help in the fight against the spread of HIV

  2. Humbled by the Past, Inspired by the Future

    Reflections on a ten-year company milestone by one of our leaders in Finance

    Reflections on a ten-year company milestone by one of our leaders in Finance

  3. Bringing High Quality and Affordable Biosimilars to European Patients

    Mylan and Biocon Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim

    Mylan and Biocon Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim

  4. Expanding our Focus to Support HIV Treatment in Ireland

    Mylan attends the HIV Ireland Red Ball in Dublin in Support of Irish Worlds AIDS Day

    Mylan attends the HIV Ireland Red Ball in Dublin in Support of Irish Worlds AIDS Day

  5. Mylan Damastown Plant Wins Chemical Laboratory of the Year 2018

    Damastown Quality Control team recognised to have shown best practice and innovation in Ireland's laboratories

    Damastown Quality Control team recognised to have shown best practice and innovation in Ireland's laboratories

Mylan Products

Our Products

Mylan news

News

Mylan careers

Working at Mylan

Contact Mylan

Contact Mylan

Last Updated  27/02/2015

Copyright © 2015 Mylan N.V.  All rights reserved.